AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29797519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 12 weeks
Number of subjects: 1281
Study 29797519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 8 weeks
Number of subjects: 1281
Study 29797519 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior dose adjustment groups
Number of subjects: 1281
Study 29797519 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised every 8 weeks
Number of subjects: 1281
Study 29797519 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised every 12 weeks
Number of subjects: 1281
Study 29797519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1281
Study 27894316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/physical activity intervention
Number of subjects: 1023
Study 27894316 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (Control)
Number of subjects: 1023
Study 27894316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns (African/Caribbean and Processed)
Number of subjects: 1023
Study 24257725 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 181
Study 24257725 — intervention group
Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 181
Study 22521071 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 629
Study 22521071 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 629
Study 20537570 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 87
Study 20537570 — intervention group
Group type: COMPARATOR
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 87
Study 18172059 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4728
Study 18172059 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 4728
Study 15844435 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (low energy laser to LU7, LI4, GB14, and GB20 bilaterally, 1.3J intensity, 10 sessions, 3 per week)
Number of subjects: 50
Study 12695240 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneas stored in organ culture for 5-12 days (group 1)
Number of subjects: 25
Study 12695240 — intervention group
Group type: COMPARATOR
Intervention: Corneas stored in organ culture for 21-24 days (group 2)
Number of subjects: 25
Study 10475721 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (3 mg)
Number of subjects: 14
Study 10475721 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 14
Study 10475721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9084525 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg + 10 ml 2% lidocaine before general anesthesia (group II)
Number of subjects: 84
Study 9084525 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg + 3 ml 2% lidocaine before wound closure (group III)
Number of subjects: 84
Study 9084525 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid analgesics (diclofenac sodium 50 mg, iv, q4h) (group I)
Number of subjects: 84
Study 2017271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine therapy (2 g i.v. 3 times weekly for 6 months)
Number of subjects: 14
Study 2017271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine therapy (1 g i.v. for 10 months after initial treatment)
Number of subjects: 14
Study 2017271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 g i.v. 3 times weekly for 6 months)
Number of subjects: 14
Study 2017271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine therapy
Number of subjects: 14
Study 6218109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of mezlocillin (1 g every eight hours)
Number of subjects: 50
Study 6218109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of mezlocillin (2 g every eight hours)
Number of subjects: 50
Study 6218109 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of administration (i.m. and i.v.)
Number of subjects: 50
Study 6218109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 50
Study 6218109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of mezlocillin
Number of subjects: 50
Study 31884075 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 80
Study 31884075 — intervention group
Group type: COMPARATOR
Intervention: Turkish music
Number of subjects: 80
Study 31884075 — intervention group
Group type: COMPARATOR
Intervention: Soft rock music
Number of subjects: 80
Study 31884075 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 80
Study 31584538 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 31584538 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 0
Study 31584538 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 31584538 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 0
Study 27682227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st group (EDSS 0, 1)
Number of subjects: 959
Study 27682227 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd group (EDSS 1.5, 2)
Number of subjects: 959
Study 27682227 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd group (EDSS 2.5, 3)
Number of subjects: 959
Study 27682227 — intervention group
Group type: EXPERIMENTAL
Intervention: 4th group (EDSS ≥3.5)
Number of subjects: 959
Study 26137956 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3241 600 mg orally twice a day for 8 weeks
Number of subjects: 24
Study 26137956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (0.25 mg/kg)
Number of subjects: 90
Study 24858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2μgm/kg)
Number of subjects: 90
Study 24858149 — intervention group
Group type: COMPARATOR
Intervention: Control (10ml of 0.9% saline)
Number of subjects: 90
Study 22292526 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. alteplase (rt-PA) at a dosage of 0.9 mg/kg of body weight
Number of subjects: 600
Study 22292526 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment according to national guidelines
Number of subjects: 600
Study 22292526 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. alteplase (rt-PA)
Number of subjects: 600
Study 19274758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 655
Study 19274758 — intervention group
Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 655
Study 17584058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-alpha monoclonal antibodies
Number of subjects: 0
Study 15132753 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 10) trained their respiratory muscles via 20, 45 min sessions of hyperpnea
Number of subjects: 20
Study 15132753 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 4) underwent 'sham' training (20, 5 min sessions)
Number of subjects: 20
Study 15132753 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6) did no training
Number of subjects: 20
Study 15020186 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders for vaccination doses
Number of subjects: 0
Study 15020186 — intervention group
Group type: COMPARATOR
Intervention: Control 2001 (no SMS reminders)
Number of subjects: 0
Study 15020186 — intervention group
Group type: COMPARATOR
Intervention: Control 2000 (no SMS reminders)
Number of subjects: 0
Study 10479167 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-alpha
Number of subjects: 180
Study 10479167 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 180
Study 10479167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with low-dose IFN-alpha
Number of subjects: 180
Study 8743976 — intervention group
Group type: EXPERIMENTAL
Intervention: TBARS concentration in subretinal fluid (SF)
Number of subjects: 38
Study 8743976 — intervention group
Group type: EXPERIMENTAL
Intervention: TBARS concentration in SF
Number of subjects: 38
Study 8743976 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TBARS and protein contents in SF
Number of subjects: 38
Study 8743976 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolution time of retinal detachment
Number of subjects: 38
Study 1820675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg intramuscular)
Number of subjects: 0
Study 1820675 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 0
Study 6293073 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy with tamoxifen and drostanolone propionate (n = 34)
Number of subjects: 98
Study 6293073 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with the CMF protocol (n = 30)
Number of subjects: 98
Study 6293073 — intervention group
Group type: COMPARATOR
Intervention: Combination of hormonal therapy and chemotherapy (n = 34)
Number of subjects: 98
Study 31964377 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 31587960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruder Compress twice a day
Number of subjects: 51
Study 31587960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruder Compress once a day
Number of subjects: 51
Study 31587960 — intervention group
Group type: COMPARATOR
Intervention: Warm washcloth used for ten minutes twice a day without reheating
Number of subjects: 51
Study 31587960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruder Compress (both groups)
Number of subjects: 51
Study 31587960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruder Compress twice daily vs once daily
Number of subjects: 51
Study 31587960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruder Compress
Number of subjects: 51
Study 29748349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 2002
Study 29748349 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 2002
Study 26524618 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief couples intervention
Number of subjects: 215
Study 26524618 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 215
Study 24345602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention targeting nutrition and physical activity environment, social environment, individual knowledge, attitudes and skills
Number of subjects: 782
Study 24345602 — intervention group
Group type: COMPARATOR
Intervention: Materials only condition (control)
Number of subjects: 782
Study 21343342 — intervention group
Group type: EXPERIMENTAL
Intervention: A0001 (α-tocopherylquinone) at doses of 0.25 g and 0.5 g under fasted state; 0.5 g to 6 g with high-fat meal
Number of subjects: 10
Study 21343342 — intervention group
Group type: EXPERIMENTAL
Intervention: A0001 (α-tocopherylquinone) administered in divided doses (0.735 g, 3 times per day)
Number of subjects: 10
Study 21343342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19903574 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg once daily
Number of subjects: 270
Study 19903574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 17378175 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody A33 in Phase I trial
Number of subjects: 0
Study 17378175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapies in Phase II trial
Number of subjects: 0
Study 17378175 — intervention group
Group type: COMPARATOR
Intervention: New therapy using newly developed material in Phase III trial
Number of subjects: 0
Study 17378175 — intervention group
Group type: COMPARATOR
Intervention: Antihypertension agents in Phase III trial
Number of subjects: 0
Study 16253589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent implantation
Number of subjects: 45
Study 11867968 — intervention group
Group type: EXPERIMENTAL
Intervention: minocycline 100/50 mg
Number of subjects: 86
Study 11867968 — intervention group
Group type: COMPARATOR
Intervention: lymecycline 300 mg
Number of subjects: 86
Study 11867968 — intervention group
Group type: COMPARATOR
Intervention: minocycline 50 mg
Number of subjects: 86
Study 9865617 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZM) 500 mg/day for 2 weeks
Number of subjects: 9
Study 7830728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg twice daily)
Number of subjects: 23
Study 7830728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30531676 — intervention group
Group type: EXPERIMENTAL
Intervention: Group DS2
Number of subjects: 100
Study 30531676 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine, IL-6, TNF-a
Number of subjects: 100
Study 27537209 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) plus stretching (n = 65)
Number of subjects: 130
Study 27537209 — intervention group
Group type: COMPARATOR
Intervention: Stretching only (control group) (n = 65)
Number of subjects: 130
Study 24523666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity renal replacement therapy (RRT)
Number of subjects: 1464
Study 24523666 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity renal replacement therapy (RRT)
Number of subjects: 1464
Study 24523666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity RRT among survivors to day 90
Number of subjects: 1464
Study 24523666 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity RRT among survivors to day 90
Number of subjects: 1464
Study 24523666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity RRT
Number of subjects: 1464
Study 24523666 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity RRT
Number of subjects: 1464
Study 24523666 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 1464
Study 23013489 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate exercise program (6 months)
Number of subjects: 124
Study 23013489 — intervention group
Group type: COMPARATOR
Intervention: Delayed exercise program (6 months after usual care)
Number of subjects: 124
Study 19723080 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape Juice (5.5 mL/kg daily for 8 weeks)
Number of subjects: 40
Study 19723080 — intervention group
Group type: COMPARATOR
Intervention: Placebo Juice (isocaloric for 8 weeks)
Number of subjects: 40
Study 16951956 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosynoviorthesis (RSO) with intra‐articular radionuclide plus glucocorticoid (GC) injection
Number of subjects: 44
Study 16951956 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus glucocorticoid (GC) injection
Number of subjects: 44
Study 15316468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular sagittal split osteotomy
Number of subjects: 69
Study 15316468 — intervention group
Group type: COMPARATOR
Intervention: Herbst appliance
Number of subjects: 69
Study 11559545 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 182,780 50 mg
Number of subjects: 200
Study 11559545 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 182,780 125 mg
Number of subjects: 200
Study 11559545 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 182,780 250 mg
Number of subjects: 200
Study 11559545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 200
Study 11559545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9786257 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional long-term anticoagulation (LTA) therapy: initial intravenous standard heparin followed by warfarin on days 3 to 5, continued for 3 months.
Number of subjects: 105
Study 9786257 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation therapy: same heparin therapy followed by warfarin on days 2 to 3, continued for 6 weeks.
Number of subjects: 105
Study 9786257 — intervention group
Group type: COMPARATOR
Intervention: Short-term anticoagulation therapy
Number of subjects: 105
Study 9786257 — intervention group
Group type: COMPARATOR
Intervention: Conventional long-term anticoagulation (LTA) therapy
Number of subjects: 105
Study 8152348 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) 20 g
Number of subjects: 40
Study 8152348 — intervention group
Group type: COMPARATOR
Intervention: n-6 PUFA 20 g
Number of subjects: 40
Study 2463524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implant (VVI or DDD)
Number of subjects: 35
Study 2463524 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 35
Study 28513326 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR+NMES
Number of subjects: 20
Study 28513326 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 28513326 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES alone
Number of subjects: 20
Study 28513326 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR alone
Number of subjects: 20
Study 28836493 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an enhanced rehabilitation package (patient-held information workbook, goal-setting diary, six additional therapy sessions)
Number of subjects: 62
Study 28836493 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 62
Study 28836493 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an enhanced rehabilitation package
Number of subjects: 62
Study 26633830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude condition
Number of subjects: 61
Study 26633830 — intervention group
Group type: COMPARATOR
Intervention: Happiness condition
Number of subjects: 61
Study 24165282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen treatment for three months
Number of subjects: 30
Study 24165282 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for three months
Number of subjects: 30
Study 24165282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen treatment
Number of subjects: 30
Study 21373203 — intervention group
Group type: EXPERIMENTAL
Intervention: pulsed‐continuous arterial spin‐labelling (pCASL)
Number of subjects: 16
Study 21373203 — intervention group
Group type: COMPARATOR
Intervention: pCASL
Number of subjects: 16
Study 18210310 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic cream (lidocaine/prilocaine) applied prior to galactography in Group B (27 patients)
Number of subjects: 46
Study 18210310 — intervention group
Group type: COMPARATOR
Intervention: No anesthetic cream in Group A (19 patients)
Number of subjects: 46
Study 16088358 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene
Number of subjects: 140
Study 16088358 — intervention group
Group type: EXPERIMENTAL
Intervention: VyproII
Number of subjects: 140
Study 12826434 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic magnesium sulphate
Number of subjects: 52
Study 12826434 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 52
Study 12826434 — intervention group
Group type: COMPARATOR
Intervention: Comparison between magnesium and saline
Number of subjects: 52
Study 10755054 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenders
Number of subjects: 365
Study 10755054 — intervention group
Group type: COMPARATOR
Intervention: Non-attenders
Number of subjects: 365
Study 8660042 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine treatment
Number of subjects: 29
Study 1819153 — intervention group
Group type: COMPARATOR
Intervention: 40 mg frusemide
Number of subjects: 12
Study 1819153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet (40 mg frusemide and 5 mg amiloride)
Number of subjects: 12
Study 6345111 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid antacid (Maalox Therapeutic Concentration, 15 ml, 80 mEq, taken 7 times daily)
Number of subjects: 32
Study 6345111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taken 7 times daily)
Number of subjects: 32
Study 30126028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose peanut OIT (3000 mg)
Number of subjects: 0
Study 30126028 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose peanut OIT (300 mg)
Number of subjects: 0
Study 29098683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (target‐controlled infusion, effect‐site concentration of 0.3 ng.ml‐1)
Number of subjects: 71
Study 29098683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 71
Study 27402372 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (access to liquids and regular diet on postoperative days 1 and 2)
Number of subjects: 102
Study 27402372 — intervention group
Group type: COMPARATOR
Intervention: Standard care (introduction of a liquid diet after return of bowel activity, typically days 3-5)
Number of subjects: 102
Study 27402372 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 102
Study 27402372 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102
Study 23679896 — intervention group
Group type: EXPERIMENTAL
Intervention: briakinumab
Number of subjects: 1465
Study 23679896 — intervention group
Group type: EXPERIMENTAL
Intervention: briakinumab every 4 weeks
Number of subjects: 1465
Study 23679896 — intervention group
Group type: EXPERIMENTAL
Intervention: briakinumab every 12 weeks
Number of subjects: 1465
Study 23679896 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1465
Study 21983050 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min walking on the treadmill (exercise trial; EX)
Number of subjects: 27
Study 21983050 — intervention group
Group type: COMPARATOR
Intervention: Seated rest (control trial; CON)
Number of subjects: 27
Study 19836898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (50mg)
Number of subjects: 0
Study 19836898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18041488 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 3 mg
Number of subjects: 67